Heart Health Blood Tests: Complete Guide

The core cardiac risk blood panel

Advanced cardiac biomarkers

10-year cardiovascular risk calculators

Rather than treating each test result in isolation, doctors calculate your overall 10-year cardiovascular risk using validated calculators: ASCVD Pooled Cohort Equations (USA), SCORE2 (Europe), QRISK3 (UK). These combine: age, sex, smoking status, blood pressure, cholesterol, diabetes status and ethnicity to estimate your 10-year risk of heart attack or stroke. Treatment decisions (whether to start statins, aspirin, etc.) are largely based on this overall risk, not individual test values alone.

How often to test

Questions to ask your doctor

• What is my 10-year cardiovascular risk?
• Should I be on a statin?
• What is my Lp(a) level?
• Is my hs-CRP elevated?
• What lifestyle changes will lower my cardiac risk most effectively?

References

Sources cited on this page. PubMed links open the original abstract.

1. Roth GA, Johnson C, Abajobir A, et al. Global, regional, and national burden of cardiovascular diseases for 10 causes, 1990 to 2015. J Am Coll Cardiol. 2017;70(1):1–25. PMID 28527533 · doi:10.1016/j.jacc.2017.04.052

Troponin – the gold standard for heart muscle injury

Cardiac troponin T and troponin I are structural proteins found exclusively in the myocardium (heart muscle). When heart cells die – as in myocardial infarction (MI) – troponin is released into the bloodstream. High-sensitivity troponin (hs-cTnT or hs-cTnI) assays can detect troponin at concentrations 10–100 times lower than previous generation tests, enabling diagnosis of MI earlier and with greater precision.

The high-sensitivity era has changed the 0/3-hour and 0/1-hour rapid MI rule-out algorithms. A troponin rise and fall pattern (at least one value above the 99th centile of a healthy population, with a significant change between serial measurements) is required to diagnose type 1 MI (plaque rupture) – a single elevated troponin without a dynamic pattern may indicate chronic myocardial injury (heart failure, CKD, myocarditis, pulmonary embolism) rather than an acute event.

BNP and NT-proBNP – markers of cardiac stretching

B-type natriuretic peptide (BNP) and its inactive precursor fragment (NT-proBNP) are released by ventricular myocytes in response to wall stress – caused by volume or pressure overload. They are the most diagnostically useful blood tests for heart failure, with critical rule-out and rule-in values:

• NT-proBNP below 125 pg/mL (or BNP below 35 pg/mL): Heart failure is highly unlikely. The negative predictive value approaches 99% in the NICE-recommended diagnostic pathway.
• NT-proBNP above 2000 pg/mL (or BNP above 400 pg/mL): Acute decompensated heart failure is likely; immediate echocardiography and treatment is indicated.
• NT-proBNP 125–2000 pg/mL: Intermediate range – echocardiography is required to confirm or exclude heart failure.

Natriuretic peptides are also elevated by atrial fibrillation, pulmonary embolism, right heart failure, and severe renal impairment – they are not heart-failure-specific. Obesity reduces BNP levels (adipose tissue clears BNP); values in obese patients may underestimate heart failure severity.

The lipid panel and cardiovascular risk

The standard lipid panel (total cholesterol, HDL, LDL, triglycerides) is combined with blood pressure, diabetes status, and other risk factors in the QRISK3 calculator to generate a 10-year cardiovascular risk score. A score above 10% triggers a NICE recommendation to offer statin therapy. However, for patients with established cardiovascular disease (prior MI, stroke, stable angina, or peripheral arterial disease), statins are recommended regardless of baseline cholesterol – the risk-reduction benefit is proven at all cholesterol levels in this population. The target in established CVD: LDL below 2.0 mmol/L or at least 50% LDL reduction from baseline, using high-intensity statins (atorvastatin 40–80 mg or rosuvastatin 20–40 mg).